Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DIAB-PHC1
- Development stage
- Phase 3
- Lead developer
- Hamdard University
- Modality
- Peptides, Small Molecules
- Administration
- Oral
01
Overview
DIAB-PHC1 is a novel polyherbal formulation developed by Hamdard University for the management of Type 2 Diabetes Mellitus. It is a hard gelatin capsule containing equal proportions of four standardized herbal extracts: *Syzygium cumini* (Jamun), *Momordica charantia* (Bitter melon), *Wrightia tinctoria* (Pala indigo), and *Gymnema sylvestre* (Gurmar). These ingredients are traditionally recognized for their hypoglycemic properties, which include insulin-mimetic effects, stimulation of insulin secretion from pancreatic beta cells, and inhibition of intestinal glucose absorption. The formulation is currently being evaluated in Phase 3 clinical trials to compare its efficacy and safety against metformin in achieving glycemic control and reducing fasting blood glucose levels in adult patients.
- Other names
- Polyherbal Anti-Diabetic FormulationHamdard Polyherbal Capsule
02
Targets
AMPK (Adenosine monophosphate–activated protein kinase)SLC5A1 (Sodium Glucose Cotransporter 1)INSR (Insulin receptor)
Beyond the preview
Go deeper on DIAB-PHC1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DIAB-PHC1.